NACDS Foundation supports NCL’s medication adherence awareness campaign
ALEXANDRIA, Va. The charitable arm of the National Association of Chain Drug Stores announced its $1 million contribution to the National Consumers League’s medication adherence awareness campaign.
NACDS Foundation said that the NCL is leading the national multimedia effort targeting people with chronic conditions and healthcare practitioners — with additional intensive outreach in a handful of markets across the country — to inform consumers of the possible health and financial burdens that can be experienced when medication is not correctly taken.
Poor medication adherence is estimated to cost the healthcare system $290 billion a year, according to the New England Healthcare Institute.
“Helping to raise public awareness about the importance of taking prescriptions as prescribed by their doctors is one of our top priorities at the NACDS Foundation, and we are proud to be a major supporter of the campaign,” said Edith Rosato, president of the NACDS Foundation. “It is vital to public health to chip away at the hurdles preventing consumers from taking medication as prescribed and improving their health and lowering overall healthcare costs. The Foundation looks forward to actively engaging in the campaign and helping to ensure its success.”
Strativa enters license, supply agreement with Sobi
WOODCLIFF LAKE, N.J. Strativa Pharmaceuticals is working with a Swedish drug maker to develop and commercialize a prescription vitamin supplement, Strativa said Tuesday.
The company said it had signed a license and supply agreement with Swedish Orphan Biovitrum, also known as Sobi, concerning European rights to Strativa’s Nascobal (cyanocobalamin), a vitamin B12 nasal spray.
The supplement is approved for treating vitamin B12 deficiency, designed as a once-weekly alternative to injections. Vitamin B12 deficiency usually results from pernicious anemia, a strict vegetarian diet and poor absorption of the nutrient resulting from such medical conditions as HIV infection, Crohn’s disease, multiple sclerosis and gastrectomy.
PerformRx receives PBM accreditation from URAC
PHILADELPHIA A full-service pharmacy benefit manager received its second accreditation from an independent, nonprofit healthcare-accrediting organization.
PerformRx said that its pharmacy benefit management accreditation from URAC indicated that PerformRx’s PBM business demonstrated a commitment to quality services. “This accreditation serves as a clear sign that PerformRx is committed to providing the best possible service to our existing and future customers,” said Mesfin Tegenu, PerformRx president. “The URAC evaluation is an incredibly rigorous process that evaluates the organization at all levels, and to wear the URAC seal is a mark of distinction for our company.”
In conjunction with its PBM accreditation, PerformRx also applied for URAC’s drug therapy management accreditation. PerformRx’s DTM program improves therapeutic outcomes for members by evaluating drug dose, method of delivery, cost effectiveness and other factors, the company said, adding that obtaining the DTM accreditation will allow PerformRx to demonstrate the high quality and effectiveness of its DTM program.